Browse Ongoing Research Studies & Apply to See If You Qualify

Your participation in clinical trials will help to advance medical research, help find new treatments and medications, and help us learn more information about eye conditions.

Qualified participants will receive compensation for time and travel and receive access to study related care and medications at no cost.

Browse our ongoing studies and apply to see if you qualify.

PERSISTENT CORNEAL EPITHELIAL DEFECT STUDY
NEUROTROPHIC KERATOPATHY STUDY

Application for research studies

Apply below to see if you qualify.

Research Form

Name
This field is for validation purposes and should be left unchanged.
Select Research Study*
- First name*
  Your Full Legal Name
- Last name*
- Phone number **
- Email **
- *Date of Birth*
  MM slash DD slash YYYY
*Gender*
- Male
- Female
Prefered contact method*
- Email
- Phone
I agree and consent to phone and email correspondence with regard to participation in any of the studies only. Your personal information will not be used for any purpose other than to contact you.*
I agree and consent to phone and email correspondence with regard to participation in any of the studies only. Your personal information will not be used for any purpose other than to contact you.

Currently Enrolling Studies

Neurotrophic Keratopathy Study (SEER-2 / RGN-259)

Sponsor: ReGenTree, LLC

This study is for patients with Neurotrophic Keratopathy, a condition where damage to the corneal nerves prevents the eye from healing properly. Because the eye may not feel pain normally, small injuries can worsen over time and become difficult to treat. The investigational treatment, RGN-259, is an eye drop designed to support the eye’s natural healing process, helping repair the surface of the cornea and improve overall eye health. The goal is to promote faster healing, reduce complications, and potentially improve vision and comfort.

Neurotrophic Keratopathy Study.pdf

Persistent Corneal Epithelial Defect Study (GLK-601-01 / NEXAGON)

Sponsor: Glaukos Corporation

This study is for patients with Persistent Corneal Epithelial Defects (PCED), a condition where the surface layer of the eye does not heal despite ongoing treatment. This can lead to discomfort, risk of infection, and vision problems. The investigational medication, NEXAGON, is designed to help stimulate healing in the cornea and close these defects when other treatments have not been successful. Participants will continue receiving their regular eye care while exploring a new option that may improve healing and protect long-term vision.

Persistent Corneal Epithelial Defect Study - GLAUKOS.pdf